Thus, immunologically targeting CSCs while simultaneously blocking PD-1/PD-L1 and/or CTLA-4-mediated immune suppression may significantly enhance the outcome of current cancer immunotherapies (38). The gene discussed is PDCD1; the disease is cancer.